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Abstract
Background: Gurigumu-7 is an important traditional Mongolian medicine frequently used for liver diseases.
However, the pharmacological effects and the bioactive constituents are not well understood.
Method: This research was to use CCl4-induced liver damage in mice to investigate the hepatoprotective effects of
Gurigumu-7 and the methanol eluted fraction from a DIAION column of an extract of Gurigumu-7 (MF). The chemical
constituents of MF were analyzed by UPLC-MS.
Results: Pretreated orally with MF (66, 132 and 264 mg/kg) once a day for 4 days dose-dependently suppressed
CCl4-induced mice liver histopathological changes and serum aminotransferase activities (alanine transaminase:
1144.0 ± 787.2 v.s. 2461.8 ± 1072.7 U/L, p < 0.05; aspartate transaminase: 1173 ± 785.3 v.s. 2506.6 ± 1140.7 U/L, p < 0.01).
MF treated group demonstrated increased levels of SOD (108.19 ± 30.32 v.s. 75.75 ± 5.37 U/mg protein, p < 0.01) but
decreased levels of malonyldialdehyde (7.68 ± 1.95 v.s. 44.32 ± 16.68 nmol/mg protein, p < 0.01) compared to the CCl4
control group. More than 30 chemical constituents were quantified, and MF was found to be rich in ellagic acid
(297.97 mg/g), luteolin and its glucosides (35.10 mg/g), apigenin and its glucosides (>30 mg/g), ursolic acid (14.91 mg/g)
, bidenoside C (8.75 mg/g), and proanthocyanidins (15.64 mg/g in proanthocyanidin A2 equivalent).
Conclusion: The methanol eluted fraction (MF) from a DIAION column of an extract of the Mongolian
medicine-Gurigumu-7 was found to be more hepatoprotective than Gurigumu-7. The results suggested that
MF is a promising bioactive fraction for the development of new hepatoprotective medicine with better
formulation and quality control properties.
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Background
Gurigumu-7 is an ethnic compound medicine frequently
used for liver diseases in the Mongolian and Tibetan
traditional medical settings. It is comprised of seven in-
dividual traditional medicines, the flower of Carthamus
tinctorius L. (Safflower), the fruit of Terminalia chebula
Retz. (Fructus chebulae), the flower of Scabiosa comosa
Fisch. ex Roem. & Schult. (Flos scabiosae), the aerial part
of Ephedra sinica Stapf (Herba ephedrae), the aerial part
of Viola yezoensis Maxim. (Herba violae), gypsum and
the caulis of Clematis armandii Franch (Caulis clematidis
armandii).
Safflower is one of the most frequently used herbal
drugs found in traditional medicine prescriptions for its
function to improve circulation and lower blood pressure
[1, 2]. The major flavonoid constituents of safflower were
reported to have hepatoprotective effects on CCl4-induced
liver injury [3]. Fructus chebulae has been used in trad-
itional medicine for intestinal and hepatic detoxification,
diarrhea, cough, sore throat and various ailments [4].
Fructus chebulae is rich in phenolic compounds which
were reported to have anti-viral activities against hepatitis
C and other viruses [5–7]. Flos scabiosae is used mainly
for liver diseases in traditional medicine [8]. Phenolics
[9, 10] and triterpene compounds [11] were reported as
the bioactive constituents of Flos scabiosae. Herba ephe-
drae has been used to relief symptoms of colds [12] due to
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the nasal decongesting and bronchodilating effects of its
alkaloid constituents, ephedrine and related compounds.
However, these sympathomimetic alkaloids may cause side
effects to central nervous system. Renewed interest in
herba ephedrae has come from new pharmacological
findings that this herb could decrease uraemic toxins
and showed anti-inflammatory activity due to its proantho-
cyanidin constituents [13–16]. Herba violae has been used
for boils, carbuncles, hepatitis and other infections in trad-
itional Chinese medicine [17]. The flavonoid constituents
were reported to be the bioactive constituents of Herba
violae for antibacterial and antioxidant activities [18–20].
Caulis clematidis armandii has been traditionally used
mainly for inflammatory-associated diseases and the
phenolic constituents were reported to be its bioactive
constituents [21, 22]. Gurigumu-7 was reported have
the effect to decrease serum aminotransferase activities
in CCl4-induced mice [23]. However, the bioactive frac-
tion, bioactive constituents and mechanism of action of
Gurigumu-7 have not been revealed.
Composed of 7 raw materials, Gurigumu-7 has to be
administered in large volumes and the taste is unpleasant.
Moreover, it is hard to establish a quality control method
for Gurigumu-7, as each of the component herbal medi-
cine could contain hundreds of chemical constituents. It
is necessary to find out the bioactive fraction for the possi-
bility to reduce the dosage and to simplify the quality con-
trol method. In the present study, we used macroporous
resin to separate Gurigumu-7 extract to 3 fractions and
tested the hepatoprotective effects of these fractions. The
most active fraction, MF (methanol eluted fraction), was
further investigated in detail for its in vivo protective ef-
fects on liver damage induced by carbon tetrachloride and
compared the effect with Gurigumu-7. The chemical con-
stituents, antioxidant activity and ability to increase liver
antioxidase load of MF were also investigated.
Methods
Chemicals and instruments
Extraction solvents were of analytical grade from XiLong
chemical Co. Ltd. (Guangdong, China). Silymarin was ob-
tained from Sigma-Aldrich (SIGMA-ALDRICH, Co., China)
and used as a positive control in this research. UPLC-DAD-
ESI-MS experiments were performed on an Agilent
1290 infinity UPLC system (Agilent, USA). Absorbance
was measured with a microplate reader (DNM-9602,
Beijing Pu Long new technology Co. Ltd., Beijing, China).
A wan-neng pulverizer (Zhejiang Yi Li Co. Ltd., Zhejiang,
China) was used for grinding medicines.
Plant material
The seven medicines to formulate Gurigumu-7 in this
research were supplied by Kulun Mongolian medicine
factory, Inner Mongolia, China and identified by the
authors through examining the morphological character-
istics, anlyzing the UHPLC-MS of the plant extracts, and
considering the information provided by the supplier.
The voucher specimens were stored in the Laboratory of
Natural Products & Functional Foods, College of Life
Sciences, Inner Mongolia University, China, as followings:
the flower of Carthamus tinctorius L (voucher specimen
number NPFFC-2); the fruit of Terminalia chebula
Retz (voucher specimen NPFFT-1); Gypsum (99.5 % of
CaSO4•2H2O content as determined by the method de-
scribed in Chinese pharmacopeia, voucher specimen
number NPFFG-1); the aerial part of Ephedra sinica
Stapf (voucher specimen number NPFFE-1); the aerial
part of Viola yezoensis Maxim (voucher specimen num-
ber NPFFV-1); the flower of Scabiosa comosa Fisch. ex
Roem. & Schult. (voucher specimen number NPFFS-1);
the caulis of Clematis armandii Franch (voucher specimen
number NPFFC-3).
Preparation of samples
Gurigumu-7 was prepared according to the documented
prescription [1] by mixing the individual medicines in the
following ratio: Safflower 25 g – Gypsum 15 g – Herba
ephedrae 15 g – Herba violae 15 g – Fructus chebulae
15 g – Flos scabiosae 10 g – Caulis clematidis armandii
10 g, and grinding the mixture to powder.
MF (methanol eluted fraction from a DIAION column
of Gurigumu-7 extract) was prepared as following:
Gurigumu-7 was extracted with methanol under reflux
(70 °C) for three times (2 h, 1 h and 30 min, respectively).
The pooled methanol solution was concentrated under
vacuum (40 °C) to get the methanol extract (10.33 g)
which was subjected to a macroporous resin (DIAION
HP20) column eluted with H2O, H2O–MeOH 1:1 and
MeOH. The MeOH eluted part was concentrated under
vacuum (40 °C) to get MF as a brown powder (1.78 g).
Animals and treatments
Six-week-old male scxk (meng) 2002–0001 mice (weighing
30 ± 5 g) were purchased from the Animal Center of Inner
Mongolia University, China. The mice were housed in
clean cages accessing to food and water ad libitum and
acclimated to the temperature (22 ± 2 °C) with 12 h
light/dark cycles for one week. The animals were cared for
in accordance with the “guidelines for animal experiments”
and the experimental procedures were approved by the
Animal Ethics Committee of Inner Mongolia University
(approval number 2016004). One hundred and twenty
mice were randomly divided into two groups named ex-
periment 1 and 2 (e1 and e2). E1 and e2 were further
randomly divided into six groups with ten mice in each
group, respectively. Mice of groups 1 and 2 from e1 and
e2 were given with 0.5 ml saline/day, group 3 from e1 and
e2 were given with 17 mg/kg silymarin. Groups 4, 5 and 6
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from e1 were treated with Gurigumu-7 powder (270.84,
541.68, 1083.36 mg/kg, respectively). Groups 4, 5 and 6
from e2 were treated with 66, 132 and 264 mg/kg of MF,
respectively. Each group received the appropriate vehicle
or sample daily by gastric intubations for 4 days. After 1 h
of the medication in the forth day, CCl4 (125 μl, 1 % in oil)
was given by intraperitoneal injection to mice except
for the mice in group 1 which were given oil only. Whole
blood was collected for biochemical analysis from the
orbit 16 h later after drug administration, and the liver
tissue was cut and immediately fixed in 10 % neutral
formalin for histopathology study.
Serum biochemistry
The blood samples were put standing for one hour and the
serum was separated by centrifugation (WiseSpin®Personal
Table Top Centrifuges, CF-10, DAIHAN Scientific, Co.,
Ltd) under 12225 g for 5 min. Serum alanine transaminase
(ALT) and aspartate transaminase (AST) were measured in
Hospital of Inner Mongolia University using standard
clinical method.
Determination of malondialdehyde (MDA) and superoxide
dismutase (SOD) in liver homogenate
The liver tissue samples were homogenized with cold
saline. The homogenates were centrifuged at 3000 rpm
at 4 °C for 10 min and the supernatant was kept at −80 °C
until use. The supernatant was used for the measurement
of MDA and SOD using commercial kits (Jiancheng
Institute of Biotechnology, Nanjing, China) following the
supplier’s instructions.
Histological examinations
Liver tissues from e2 were fixed in 10 % (v/v) neutral
phosphate buffer formalin and the liver pathological sec-
tion were prepared and examined by the First Affiliated
Hospital of Inner Mongolia Medical University – Cancer
Hospital.
DPPH radical scavenging assay
The DPPH scavenging activity of MF and the Gurigumu-7
extract were measured at the concentrations of 50, 25,
12.5, 6.25, 3.125 μg/mL using reported method [24].
Briefly, 10 μl of sample solution in DMSO was mixed with
190 μl of the ethanol solution of DPPH. After 20 min, the
absorbance (A) at 540 nm was measured and the per-
centage of DPPH scavenged (S%) was calculated using
the following formula:
S% ¼ 100 Acontrol‐Asample
 
=Acontrol
Where Acontrol was the average absorbance of wells
without sample.
Results represented as EC50 (sample concentration that
produced 50 % of radical scavenging activity) were found
from the S%-versus-concentration curves.
Preparation of Sample Solutions for UPLC-DAD-MS Analysis
The 3 fractions of Gurigumu-7 were dissolved in DMSO
(10 μg:1 ml) containing 1 μg/mL of abrusin 2″-O-β-
apioside [25] as internal standard. Standard stock solu-
tions were prepared in DMSO containing 1 μg/mL of
internal standard. The solutions were filtrated through
0.22 μm microfilters to obtain the sample solutions for
ultra-high performance liquid chromatography-diode array
detector-triple quadruple mass spectrometry (UPLC-DAD-
QQQMS) analysis.
UPLC-DAD-QQQMS analysis
The chemical compositions of the three fractions from
a DIAION column chromatography of Gurigumu-7
were analyzed by UPLC-DAD-QQQMS using an Agilent
ZORBAX SB-C18 RRHT column (50 × 2.1 mm i.d.; particle
size 1.8 μm) at 30 °C. The constituents were quantified by
Table 1 Effects of Gurigumu-7 powder on serum transaminases
in CCl4-injured mice (e1)
Groups Parameter (U/L)
ALT AST
Saline-treated mice 32.1 ± 8.4## 141.6 ± 59.0##
CCl4-treated mice 3822.0 ± 1494.8 4059.6 ± 1408.3
CCl4-17 mg/kg silymarin-treated
mice
2205.0 ± 912.2* 2034.0 ± 1262.9*
CCl4-270.84 mg/kg Gurigumu-7
-treated mice
3438.0 ± 1742.0 3586.0 ± 2170.1
CCl4-541.68 mg/kg Gurigumu-7
-treated mice
2933.2 ± 1405.0 2910.0 ± 1652.8
CCl4-1083.36 mg/kg Gurigumu-7
-treated mice
2345.1 ± 1449.8 2290.2 ± 1519.7*
The values are expressed as mean ± S.D
*significant different (p <0.05) from CCl4 control group
##highly significant different (p <0.01) from CCl4 control group




Saline-treated mice 30.4 ± 4.0## 123.0 ± 24.3##
CCl4-treated mice 2461.8 ± 1072.7 2506.6 ± 1140.7
CCl4-17 mg/kg silymarin-treated
mice
1115.6 ± 291.3** 1230.6 ± 437.6**
CCl4-66 mg/kg MF-treated mice 2766.0 ± 1909.7 2482.8 ± 1853.3
CCl4-132 mg/kg MF-treated mice 1929.0 ± 799.8 1748.0 ± 694.8
CCl4-264 mg/kg MF-treated mice 1144.0 ± 787.2* 1173 ± 785.3**
The values are expressed as mean ± S.D
*significant different (p <0.05) from CCl4 control group
##,**highly significant different (p <0.01) from CCl4 control group
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UHPLC-QQQMS in multiple reaction monitoring (MRM)
mode using reported analysis conditions and standard
compounds for the constituents of Safflower [26, 27],
Fructus chebulae [28], Flos scabiosae [10], Herba ephedrae
[29], and Herba violae [20, 30]. For the quantification of
calceorioside B in Caulis clematidis armandii, ESIMS full
scan method was used and the extract was compared
with a standard compound from Beijing Century Aoke
Biotechnology Co. Ltd (Beijing, China). Data were presented
as the average values from three repeat quantifications.
Measurement of proanthocyanidin A2 equivalents
Proanthocyanidin A2 equivalents were measured by n-
BuOH–HCl–Fe III method [31, 32]. Briefly, to a 1.5 ml
centrifuge tube was added 0.5 mg of sample, 1.2 ml of a
solution of n-BuOH-conc. HCl (95:5, v/v) and 40 μl of
ferric ammonium sulphate reagent (2 % w/v in 2 M
HCl). The tubes were closely capped with top clips and
heated at 95 °C for 40 min. Absorbance of the released
cyanidin was measured at 560 nm by a Thermo Scientific
Varioskan Flash (Thermo Fisher Scientific Oy D.O. Box100,
FI-01621 Vantaa, Finland). The flavan-3-ol contents were
expressed as proanthocyanidin A2 equivalents as A-type
proanthocyanidins were reported from one of the medi-
cines in Gurigumu-7, Herba ephedrae [15, 16]. Proantho-
cyanidin A2 equivalents of samples were calculated
from the absorbance – concentration curve of proantho-
cyanidin A2.
Statistical analysis
Statistical analysis of the data was accomplished by mean
of the SPSS® statistical software package. The data are
presented as the means ± SD. Differences where P < 0.05
were considered statistically significant.
Results
The effect of gurigumu-7 and MF on the increased levels
of serum transaminases induced with CCl4
As shown in Tables 1 and 2, the serum ALT and AST
levels of CCl4-treated groups were significantly higher
(P < 0.01) than saline-treated groups. In e1, the serum
ALT and AST levels of mice treated with silymarin were
lower (P < 0.05) than those treated with CCl4 only. Pre-
treatment with 1083.36 mg · kg−1 of Gurigumu-7 powder
Table 3 Liver SOD and MDA levels in mouse treated with CCl4
and MF
Groups SOD (U/mg protein) MDA (nmol/mg protein)
Saline-treated mice 114.23 ± 2.75## 7.08 ± 0.04##
CCl4-treated mice 75.75 ± 5.37 44.32 ± 16.68
CCl4-17 mg/kg silymarin
treated mice
102.41 ± 24.66* 12.47 ± 3.27**
CCl4-66 mg/kg MF
treated mice
82.46 ± 15.48 19.31 ± 6.58**
CCl4-132 mg/kg MF
treated mice
93.39 ± 40.91 8.58 ± 1.11**
CCl4-264 mg/kg MF
treated mice
108.19 ± 30.32** 7.68 ± 1.95**
The values are expressed as mean ± S.D
*significant different (p <0.05) from CCl4 control group
##,**highly significant different (p <0.01) from CCl4 control group
Fig. 1 Effects of silymarin and different doses of MF on the liver histological changes in CCl4 treatment mice. a normal group; b CCl4-intoxicated group;
c CCl4 + Silymarin (17 mg/kg); d CCl4+ MF (66 mg/kg); e CCl4+ MF (132 mg/kg). f CCl4+ MF (264 mg/kg)
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Table 4 Concentrations (mg/g unless otherwise indicated) of Gurigumu-7 constituents in the three fractions
Main source constituents H2O fraction 1:1 fraction MF
Safflower protocatechuic acid 0.00 ± 0.00 1.61 ± 0.01 1.15 ± 0.00
hydroxysafflor yellow A nd 12.77 ± 0.01 0.19 ± 0.02
6-hydroxykaempfer 3,6,7-triglucoside 0.17 ± 0.00 2.09 ± 0.00 0.08 ± 0.01
kaempferol-3-O-D-glucoside nd 0.082 ± 0.04 3.13 ± 0.01
bidenoside C nd nd 8.75 ± 0.01
kaempferol-3-O-rutinocoside 0.06 ± 0.01 0.65 ± 0.05 2.86 ± 0.04
6-hydroxykaempferol-3-rutinoside-6-glucoside nd 1.63 ± 0.02 0.22 ± 0.02
6-hydroxykaempferol-3,6-diglucoside nd 0.28 ± 0.039 0.04 ± 0.03
linolic acid nd 0.21 ± 0.03 26.2 ± 0.09
α-linolenic acid nd 0.20 ± 0.08 25.5 ± 0.13
oleic acid 0.36 ± 0.07 0.38 ± 0.10 3.13 ± 0.09
Fructus chebulae chebulic acid 12.81 ± 0.02 0.74 ± 0.00 0.076 ± 0.00
gallic acid 7.68 ± 0.02 12.23 ± 0.02 nd
chebumeinin A 0.09 ± 0.00 0.67 ± 0.01 0.09 ± 0.00
chebumeinin B 0.24 ± 0.01 0.48 ± 0.01 0.24 ± 0.01
casuarinin nd 2.35 ± 0.01 1.88 ± 0.01
corilagin 3.48 ± 0.01 7.30 ± 0.02 3.50 ± 0.02
chebulagic acid 2.25 ± 0.01 6.05 ± 0.01 2.38 ± 0.01
pentagalloyl glucose 0.86 ± 0.01 1.06 ± 0.01 0.94 ± 0.02
ellagic acid nd 82.14 ± 0.80 297.97 ± 1.84
Flos scabiosae caffeic acid nd 0.46 ± 0.00 nd
quinic acid nd 2.28 ± 0.01 nd
chlorogenic acid 0.87 ± 0.01 32.08 ± 0.58 0.83 ± 0.02
p-coumaric acid 0.24 ± 0.00 0.34 ± 0.00 0.67 ± 0.01
luteolin-6-C-glucoside nd 5.54 ± 0.01 0.64 ± 0.01
quercetin-3-glucoside nd 0.98 ± 0.01 4.30 ± 0.01
rutin nd nd 0.05 ± 0.00
apigenin-7-arabinoglucoside nd 0.75 ± 0.00 5.38 ± 0.02
apigenin-4′-glucoside nd nd 11.59 ± 0.02
apigenin-7-glucoside nd nd 11.51 ± 0.01
luteolin-4′-O-glucoside nd 0.73 ± 0.00 16.02 ± 0.02
luteolin-7-O-glucoside nd 0.84 ± 0.01 16.12 ± 0.02
luteolin nd nd 2.96 ± 0.02
apigenin nd nd 1.59 ± 0.01
ursolic acid nd nd 14.91 ± 0.35
hederagenin/3β,23-dihydroxyursan-12-en-28-oic acid 0.01 ± 0.019 0.01 ± 0.02 1.80 ± 0.03
Herba ephedrae Ephadra alkaloids nd 98.33 ± 0.15 %a 1.67 ± 0.64 %a
Proanthocyanidin A2 equivalent nd 31.33 ± 2.62 15.64 ± 1.78
Herba violae 6,7-dihydroxycoumarin nd 25.23 ± 0.74 3.12 ± 0.02
5,5′-bi (6,7-dihydroxycoumarin) nd 0.67 ± 0.01 nd
apigenin 6,8-di-C-β-D-glucoside, 0.54 ± 0.53 %a 90.81 ± 1.01 %a 8.65 ± 0.87 %a
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significantly decreased the AST level (p <0.05). Guri-
gumu-7 was separated by DIAION column chromatog-
raphy to obtain three fractions and the methanol eluted
fraction, MF, was found to be the most effective fraction
in reducing serum transaminases, in a preliminary animal
experiment. MF was then investigated in detail in e2 and
the results are shown in Table 2. Pre-administration of
MF to mice for four days at 66, 132 and 264 mg/kg
reduced the elevation of serum ALT and AST levels dose
dependently. The serum ALT and AST levels in the
264 mg/kg MF-treated group were significantly lower
(p <0.05 and p <0.01, respectively) than CCl4-treated
group.
Effects on Superoxide Dismutase (SOD) and
Malondialdehyde (MDA) levels
In order to evaluate the effects of MF on CCl4 induced
liver oxidative stress, we examined the mouse liver levels
of SOD and MDA. SOD is an important antioxidant en-
zyme produced by living organisms to defense oxidative
stress [33]. MDA is produced by lipid peroxidation and
its level correlates with the degree of oxidative stress.
The liver SOD and MDA levels are shown in Table 3.
CCl4 treatment significantly decreased SOD activity and
increased MDA content (P < 0.01), suggesting strong oxi-
dative stress and lipid peroxidation in the CCl4 treated
group. Pretreatment with MF (66, 132 and 264 mg/kg) and
silymarin prevented this trend. The SOD levels in both
silymarin treated group and MF treated groups (264 mg/
kg) were significantly increased compared with the
CCl4 control group, and the MF treated group have
better activities. Pre-administration with silymarin and
MF caused highly significant decreases in the liver level
of MDA (P < 0.01).
Histopathological changes of mice livers
The microscopic pictures of the mice liver tissue sec-
tion are shown in Fig. 1. The cells of normal group
(group 1, Fig. 1a) were arranged regularly without obvious
degeneration and necrosis. In CCl4-intoxicated group
(group 2, Fig. 1b), the liver lobule was around the central
vein and there was a wide range of focal necrosis with in-
flammatory cell and degeneration. In the positive control
group (group 3, Fig. 1c), the cells were cloudy swelling,
but the structure was intact. As the dose of MF increased
(Fig. 1d, e, f ), the morphological changes became less.
Components of MF
More than 30 chemical constituents were quantified by
UHPLC-QQQMS and colorimetric method for MF and
the other two fractions from the DIAION column. The
results are listed in Table 4. MF was found to be especially
rich in ellagic acid (297.97 mg/g), luteolin and its glucosides
(35.10 mg/g), apigenin and its glucosides (30.07 mg/g),
ursolic acid (14.91 mg/g), and bidenoside C (8.75 mg/g).
Among these, the triterpene compound ursolic acid (a
major constituent of Flos scabiosae) and the acetylenic
compound bidenoside C (a constituent of Safflower) were
found exclusively in MF. MF also contained large amount
of proanthocyanidins (15.64 mg/g in proanthocyanidin A2
equivalent) that may come from Herba ephedrae, a plant
known to contain A-type proanthocyanidins [16]. It is in-
teresting to note that almost all ephedra alkaloids (98.33 %)
were eluted out to the H2O-MeOH 1:1 fraction, leaving MF
almost free of ephedrine and related alkaloids.
MF demonstrated stronger DPPH scavenging activity
(EC50 = 39.79 μg/mL) than Gurigumu-7 extract (EC50 =
43.69 μg/mL), which may come from the high contents
of phenolic compounds such as ellagic acid and the fla-
vonoids, luteolin and its glucosides, as well as apigenin
and its glucosides in MF (Table 5).
Discussion
The ethnic compound medicine, Gurigumu-7, has a
long history to be used for liver diseases in Mongolian
and Tibetan medical clinics [1]. The formulations of
Gurigumu-7 on the market are bitter and astringent
powder or bolus with a large dosage indicated (5 g every
time for example). They are unpleasant to swallow and
the administration may affect appetites. In this study, we
separated Gurigumu-7 extract into three fractions by
DIAION column and found MF, the methanol eluted frac-
tion, demonstrated better bioactivity than Gurigumu-7.
From 10.33 g of Gurigumu-7 extract, 1.78 g of MF was
obtained, and indeed, a much lower dose (264 mg/kg) of
MF showed more potent hepato-protective activity than
Gurigumu-7 at 1083.36 mg/kg. These results indicated
that MF is one of the hepato-protective fractions of
Table 4 Concentrations (mg/g unless otherwise indicated) of Gurigumu-7 constituents in the three fractions (Continued)
apigenin 6-C-β-D-glucosyl-8-C- α-L-arabinoside/apigenin
6-C-β- D- glucosyl-8-C-β-L-arabinoside
2.88 ± 0.36 %a 48.96 ± 0.08 %a 48.16 ± 0.65 %a
apigenin 6-C-α-L-arabinosyl- 8-C-β-D-xyloside/apigenin
6,8-di-C-α-L-arabinoside
2.66 ± 0.08 %a 47.50 ± 0.45 %a 49.83 ± 0.71 %a
Caulis clematidis armandii calceolarioside B 0.18 ± 0.89 0.17 ± 0.07
nd not detectable
apercentages of these compounds were calculated according to the peak area ratios of the compounds in LC-MS
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gurigumu-7, and that administration of MF could reduce
the effective dose.
It is reported that liver tissue in CCl4 treated animals
can cause lipid peroxidation and trigger production of
MDA. Measurement of MDA levels is the most commonly
used method for the evaluation of lipid peroxidation, be-
cause MDA is the most abundant individual aldehyde
resulting from lipid peroxidation [34]. Our study showed
that acute CCl4 treatment caused an increase of liver
MDA concentration which was in agreement with re-
ported result [35]. Pretreatment with MF at the doses of
66, 132, 264 mg/kg for four consecutive days reversed
these changes. SOD which is an important in vivo anti-
oxidant enzyme is inactivated by lipid peroxides or re-
active oxygen species when CCl4 is administrated [36].
In the MF treated groups, a tendency of dose-dependent-
increase of SOD activities was observed, with the effect
of 264 mg · kg−1 being highly significant (P < 0.01). The
strong DPPH scavenging activity of MF, and the increased
liver SOD and decreased liver MDA levels of MF treated
groups suggest that the hepatoprotective effects of MF are
partly due to its antioxidant effects.
Chemical analysis revealed that MF contained large
amounts of triterpene compound-ursolic acid, as well as
phenolic compounds-ellagic acid and flavonoids (glycosides
of apigenin, luteolin and quercetin). All these natural prod-
ucts are known to have hepatoprotective activities [37–39].
The active fraction of Gurigumu 7, MF, with better antioxi-
dant and hepatoprotective activity in a much less dosage
than Gurigumu 7, could be a better choice for patients.
Conclusions
In conclusion, this study demonstrated for the first time
that the methanol eluted fraction (MF) from a DIAION
column of an extract of the Mongolian medicinal pre-
scription-Gurigumu-7 has hepatoprotective effect. MF
dose dependently decreased serum aminotransferase ac-
tivities, increased liver SOD levels and decreased liver
malonyldialdehyde levels in CCl4 treated mice. MF was
found to contain large amounts of bioactive phenolic
compounds and triterpenes which might act concertedly
for the hepatoprotective effects. The research results
provided scientific evidence for the clinic efficacy of this
Mongolian medicinal prescription for liver diseases. The
results demonstrated that MF is a promising bioactive
fraction of Gurigumu-7 for the develpment of convenient
hepatoprotective formulations.
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